Patrick Howson, PhD, is a founder and CEO of Junaxo Inc., a drug development company focused on novel therapies for Parkinson’s disease. His primary expertise lies in the outsourcing and managing research and development projects from medicinal chemistry through to Phase II clinical trials. Most recently he helped progress Cogane™ through a Phase II clinical trial in Parkinson’s disease. Dr. Howson is also a scientific associate at Toronto Western Hospital, University Health Network. Dr. Howson’s primary research interest is the development of disease-modifying therapies for neurodegenerative disorders. Dr. Howson holds a BSc (Hons.) in neuroscience from the University of Manchester, UK and a PhD in neurobiology from the University of Bristol.